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Abstract The molecular bases of the versatile functions of Rho-
like GTPases are still unknown. Using luciferase assays with rat 
3Y1 cells, we found that Racl is integrated downstream of Ras in 
the TRE (TPA response element) activation pathway. Coex-
pression of a mutant of p65PAK, PAK/RD, lacking the kinase 
domain but containing the Cdc42/Rac interactive binding (CRIB) 
region, suppressed the TRE activation and cell transformation 
caused by constitutively activated forms of Ras (RasV12) and 
Racl (RaclV12). PAK/RD is a good tool to investigate the 
signaling pathways in which Rac and Cdc42 are involved. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Small GTP-binding proteins or GTPases act as molecular 
switches in diverse cellular functions [1]. In mammalian cells, 
Rho (A, B, C isoforms), RhoE, RhoG, Rac (1, 2 isoforms), 
Cdc42 (Cdc42Hs, G25K isoforms), and TC10, have been 
identified as members of the Rho family of GTP-binding pro-
teins [1]. Microinjection experiments with Swiss 3T3 fibro-
blasts have revealed that Cdc42, Rac, and Rho control the 
formation of filopodia, membrane ruffles (lamellipodia), and 
actin stress fibers with focal adhesion complexes, respectively 
[2-6]. This dynamic rearrangement of the actin cytoskeleton is 
caused by the GTPase cascade reaction: Cdc42 activates Rac, 
which in turn activates Rho [6,7]. 
In addition to their effects on actin polymerization and 
cytoskeletal rearrangement, the Rho family of GTPases is in-
volved in the regulation of cell growth. Rac and Rho are 
required for oncogenic Ras-induced transformation, cooperat-
ing with Raf [8-11]. Rac, Rho, and Cdc42 induce Gl cell cycle 
progression and subsequent DNA synthesis [12,13]. Knowl-
edge about downstream signaling pathways stimulated by 
the Rho-like GTPases has been accumulating. Rac and 
Cdc42, but not Rho, have been shown to activate the JNK/ 
SAPK and p38/Mpk2 signaling pathways, which are triggered 
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by stress stimuli [13-18], and pp70S6K, which plays an im-
portant role in Gl cell cycle progression [19]. Rho A, Rac, and 
Cdc42 also stimulate a novel signaling pathway leading to 
transcriptional activation by SRF (serum response factor), 
which does not correlate with activation of known MAP kin-
ase cascades [20]. 
In order to understand how the Rho family members ex-
ecute these various functions, a number of candidate target 
proteins that interact with the Rho family of GTPases in a 
GTP-dependent manner have been described [21-28]. Among 
these candidate proteins, p65PAK seems to be a key molecule 
of the Rac/Cdc42 signaling pathway. p65PAK was originally 
isolated from rat brain as a serine/threonine kinase that was 
activated by the binding of GTP forms of Rac and Cdc42 [22]. 
A protein motif search using the GTPase-binding site of 
p65PAK has led to the identification of a minimum region of 
16 amino acids required for Cdc42/Rac interactive binding 
(CRIB motif). More than 25 proteins containing a similar 
motif were identified from a wide range of eukaryotes, and 
several of these proteins have been shown to bind to Cdc42 
and/or Rac in vitro in a GTP-dependent fashion [29]. 
It has been previously reported that Racl stimulates c-Jun 
transcriptional activity using GAL4-luciferase and GAL4-C-
Jun fusion protein [15]. However, to date there is no report 
showing that Racl activates the TRE (TPA response ele-
ment), which is an authentic c-Jun binding site. In this paper, 
using luciferase assays with rat 3Y1 cells, we demonstrate that 
a constitutively activated form of Racl potentiated transcrip-
tional activation via a TRE, and Racl is integrated down-
stream of Ras in the Ras-mediated TRE activation. We also 
show that a mutant of p65PAK, PAK/RD, lacking the kinase 
domain but containing the Cdc42/Rac interactive binding 
(CRIB) region, suppresses transcription via a TRE and cell 
transformation mediated by the Ras-Rac pathway. PAK/RD 
is thought to inhibit the activities of Rac/Cdc42 target pro-
teins by titrating out endogenous Rac and Cdc42. Our studies 
suggest that PAK/RD and probably similar mutants for other 
CRIB motif-containing proteins may provide good tools to 
investigate the intracellular signaling pathways in which Rac 
and Cdc42 are involved. 
2. Materials and methods 
2.1. Isolation of p65PAK cDNA 
We have recently identified a novel mammalian Ste20-related kin-
ase, YSK1 [30]. In the process of the screening of a mouse brain 
cDNA library for YSK1, we isolated a cDNA clone 16L, related 
but not identical to that encoding YSK1. Screening of a rat 3Y1 
cDNA library constructed in X ZAPII using 16L as a probe permitted 
us to isolate full-length cDNA clone (16L-11) encoding rat p65PAK 
[31]. 
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Fig. 1. Immunological detection of T7 epitope-tagged proteins. (A) COSl cells were transfected with the empty vector (lane 1), the expression 
vector for T7-tagged wild-type Rac (lane 2), T7-tagged RaclV12 (lane 3), and T7-tagged RaclN17. (B) COSl cells were transfected with the 
empty vector (lane 1), the expression vector for T7-tagged wild-type p65PAK (lane 2), and T7-tagged PAK/RD (lane 3). The same amount (100 
|xg) of each cell extract was reacted with the anti-T7 monoclonal antibody. The sizes of proteins are indicated in kDa. 
2.2. Construction of expression plasmids 
The SRHis expression vector was used for constructing all expres-
sion plasmids. The construction of the SRHis vector has been re-
ported [32]. Expressed proteins contained 6 tandem histidine residues 
and the sequence, MASMTGGQQMGR, which is an epitope from 
the gene 10 leader peptide of T7 phage, at its N-terminus. An EcoRI 
site was introduced immediately upstream of the initiation codon by 
PCR to facilitate subsequent plasmid constructions. An EcoRl-EcoRl 
cDNA fragment of p65PAK containing the entire protein-coding se-
quence was blunt-ended and introduced into the Pvull site of the 
SRHis expression vector. An EcoRl-BgM cDNA fragment (amino 
acid 1-251) corresponding to the regulatory domain (RD) of 
p65PAK was blunt-ended and introduced into the SRHis vector. A 
cDNA fragment containing the entire protein-coding region of Rac 
was obtained from rat brain cDNA by PCR amplification. Amplifi-
cation was conducted with upstream primer (5'-GCGAATTCCCC-
GAGATGCAGGCCATCAA-3') and downstream primer (5'-GC-
GAATTCGGCTCCGACATTTACAACAGC-3'), both of which 
have an EcoRI site at their 5' end. The conditions for the PCR 
reactions were 25 cycles at 94°C for 1 min, 55°C for 1 min, 72°C 
for 1 min, followed by a final step of 5 min at 72°C. The PCR frag-
ment was digested with EcoRI and subcloned into the SRHis expres-
sion vector. Mutagenesis of Gly to Val at codon 12 or of Ser to Asn at 
codon 17 in Rac was carried out by overlapping PCR. The construc-
tion of expression plasmids for RasV12 and RasN17 has been previ-
ously reported [33]. 
2.3. Immunoblot analysis 
COSl cells were transfected with the expression plasmids for epi-
tope-tagged Rac, RaclV12, RaclN17, p65PAK, or PAK/RD by elec-
troporation, and the following preparation of cell extracts were car-
ried out as described [31]. The epitope-tagged proteins were reacted 
with anti T7-tag monoclonal antibody (Novagen), and then with 
horseradish peroxidase-conjugated sheep anti-mouse Ig (Amersham), 
and visualized using ECL detection reagent (Amersham). In some 
experiments alkaline phosphatase-conjugated goat anti-mouse Ig 
(TAGO) was used as a secondary antibody, and visualized using the 
alkaline phosphatase substrate kit I (Vector laboratories). 
2.4. Luciferase assay 
The TRE-luciferase reporter plasmid contains the luciferase struc-
tural gene positioned downstream of 6 tandem repeats of synthetic 
collagenase TRE (TRE X 6) under the control of the SV40 promoter 
[34]. Rat 3Y1 cells were maintained in Dulbecco's modified Eagle's 
medium (DMEM) supplemented with 10% fetal calf serum (FCS). 
The day before transfection cells were seeded at a density of 3 x l 0 3 
cells per 6 cm dish. Transfection was carried out using the calcium 
phosphate coprecipitation method. After 6 h, the medium was re-
moved and the cells were washed twice with 3 ml of phosphate-buf-
fered saline. The cells were then rendered quiescent by incubation in 
DMEM containing 0.5% FCS for 48 h. Harvesting the cells without 
stimulation, the preparation of cell extracts and the measurement of 
luciferase activity were performed as previously described [34]. 
2.5. Colony formation assay 
NIH3T3 cells and a Ha-Ras-transformed cell line, 29-1, were grown 
in DMEM supplemented with 7%> calf serum (CS). Cells were seeded 
at a density of 5 X105 cells per 10 cm dish and co transfected with 2 itg 
of pSV2-Neo and various combinations of expression vectors for 
RasV12, RaclV12, RaclN17, p65PAK and PAK/RD using the calcium 
phosphate coprecipitation method. The total amount of transfected 
DNA was adjusted to 20 |xg per 10 cm dish with the SRHis vector. 
After 48 h culture in DMEM/7%>CS, cells were grown in the presence 
of 300 ug/ml of G418 (geneticin, Gibco BRL) for 2 weeks. The selec-
tion medium was changed every 3 days. Tissue culture plates (6 cm) 
were coated with 3 ml of an agarose mixture (2.25 X DMEM and 0.5%> 
agarose were mixed at the ratio of 1:1). G418-resistant cells were 
collected, mixed and resuspended in 2 ml of DMEM. The cell suspen-
sion was combined with 4 ml of the agarose mixture (final 0.18% 
agarose), and 1.5 ml of this mixture was overlaid onto each plate. 
The cells were plated in triplicate at a density of 1 X104 cells per dish 
and cultured for 3 weeks. The cells were fed with 1.5 ml of the 0.18% 
agarose mixture every 5 days. Colonies consisting of more than 10 
cells were scored as positive. For morphological examination, a por-
tion of G418-resistant cells were reseeded at a density of 5X105 cells 
per 10 cm dish and maintained in DMEM containing 200 (tg/ml of 
G418 for a week. 
3. Results 
3.1. PAK/RD suppresses transcriptional activation via a TRE 
Rac and Cdc42 have been implicated in activation of the 
J N K / S A P K [13-18]. Although using GAL4-luciferase and 
GAL4-c-Jun fusion protein it has been shown that c-Jun tran-
scriptional activity is potentiated by Rac and Cdc42 [15], it is 
not clear that Rac l activates the T R E , an authentic c-Jun 
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Fig. 2. Inhibitory effects of PAK/RD on the activity of TRE-luciferase by RasV12 and RaclV12. (A) Rat 3Y1 cells were cotransfected with 
1 |ig of the TREX6-luciferase reporter plasmid and 0-2 (xg of the RasV12, RaclV12, RasN17, RaclN17, or PAK/RD expression vector as in-
dicated. (B) 3Y1 cells were cotransfected with 1 ug of TRE-luc and 1.5 u,g of the RasV12 expression vector together with RasN17, RaclN17, 
or PAK/RD expression plasmid. (C) 3Y1 cells were co-transfected with 1 ug of TRE-luc and 1.5 ug of the RaclV12 expression vector together 
with RasN17, RaclN17, or PAK/RD expression plasmid. After serum starvation, cell extracts were prepared without stimulation. 
binding site. We examined whether Rac is involved in tran-
scriptional activation via a T R E using a constitutively acti-
vated and a dominant negative of R a c l , Rac 1VI2 and 
R a c l N 1 7 , respectively. The proteins of wild-type R a c l , 
Rac lV12 , and R a c l N 1 7 were expressed as T7 epitope-tagged 
proteins to facilitate immunological detection using the anti-
T7 monoclonal antibody. As shown in Fig. 1A, T7 epitope-
tagged R a c l , Rac lV12, and R a c l N 1 7 were detected as 29-
k D a proteins. 
Transcriptional activities were measured in rat 3Y1 cells 
using TRE-luciferase as a reporter gene. RasV12, a constitu-
tively activated form of Ras, activated the TRE-luciferase 
activity, consistent with the previous reports that Ras aug-
ments c-Jun activity (Fig. 2A). Rac lV12 activated T R E luci-
ferase activity without any stimulation, in a dose-dependent 
manner, but R a c l N 1 7 did not show any increase in luciferase 
activity (Fig. 2A). Rac lV12 did not activate luciferase from a 
mutated T R E (data not shown). We next examined whether 
Rac l is integrated in the Ras-mediated TRE-luciferase activa-
tion. As shown in Fig. 2B, when dominant negative forms of 
Ras (RasN17) or Rac l (Rac lN17) were cotransfected with 
RasV12, both RasN17 and R a c l N 1 7 suppressed the activa-
tion of TRE-luciferase by RasV12 in a dose-dependent man-
ner. However, when RasN17 or R a c l N 1 7 were cotransfected 
with Rac lV12, R a c l N 1 7 suppressed the T R E activation by 
Rac lV12 , whereas RasN17 did not (Fig. 2C), suggesting that 
Rac functions downstream of Ras in the T R E activation. 
We constructed a mutant , P A K / R D , which lacks the C-
terminal kinase domain, but contains the N-terminal C R I B 
region. Rac and Cdc42 bind to the CRIB region of p 6 5 P A K 
and activate its kinase activity [22,29]. It is thought that PAK7 
R D could titrate out endogenous Rac and Cdc42 and inhibit 
the functions of molecules that rely on an interaction with 
Rac and/or Cdc42 for their activation, such as p 6 5 P A K . Fig. 
IB shows that T7-tagged p 6 5 P A K and P A K / R D were detected 
as 70- and 36-kDa proteins, respectively. P A K / R D itself did 
not lead to activation of TRE-luciferase (Fig. 2A) like RasV12 
and Rac lV12. Coexpression of P A K / R D with RasV12 or 
R a c l V I 2 suppressed the activation of TRE-luciferase by 
RasV12 and R a c l V I 2 in a dose-dependent manner (Fig. 
2B,C). Coexpression of wild-type p65PAK did not suppress 
the T R E activation by RasV12 or R a c l V I 2 (data not shown). 
These results suggest that molecules, which are activated by 
binding to Rac and/or Cdc42 and involved in transcriptional 
activation via a T R E through the Ras-Rac pathway, were 
blocked by P A K / R D . 
3.2. PAK/RD inhibits cell transformation mediated by the 
Ras-Rac pathway 
We next examined the effect of P A K / R D on cell transfor-
mation induced by overexpression of Rac lV12. N I H 3T3 fi-
broblasts stably transfected with the empty vector or with 
RasV12 were used as negative and positive controls of cell 
transformation, respectively (Fig. 3A,B). As previously re-
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Fig. 3. Suppression of morphological transformation of RaclV12 transfected NIH 3T3 cells by PAK/RD. Phase contrast photographs of NIH 
3T3 cells stably transfected with (A) empty vector, (B) RasV12, (C) RaclV12, (D) p65PAK, (E) PAK/RD, and (F) RaclV12 and PAK/RD. 
Magnification: X40. 
ported [8], overexpression of RaclV12 promoted colony for-
mation on soft agar, being comparable to the result with 
RasV12 (Table 1). Cells transfected with RaclV12 showed 
an unorganized growth pattern, an increase in cell density, 
and piled up to make foci (Fig. 3C), indicating the loss of 
contact inhibition. In contrast, cells transfected with 
RaclN17, wild type p65PAK or PAK/RD did not show an 
increase in colony forming activity (Table 1). These cells dem-
Table 1 
Summary of the colony formation assay in NIH3T3 cells 
Ex 1 Ex 2 Ex 3 
Vector 
RasV12 
RaclV12 
RaclN17 
PAK 
PAK/RD 
RasV12+RaclN17 
RasV12+PAK/RD 
RaclV12+PAK/RD 
1.4 ±0.6 
21.0± 1.1 
20.6 ±2.7 
1.1±0.4 
1.0 ±0.3 
0.7±0.6 
2.2 ±0.3 
1.110.4 
9.511.6 
2.2 ±0.8 
9.211.7 
16.910.3 
1.810.4 
1.310.9 
0.410.4 
4.310.3 
2.310.3 
3.210.5 
1.910.2 
14.112.4 
22.913.0 
2.210.7 
ND 
2.310.2 
4.710.2 
6.210.4 
5.311.5 
ND, not determined. Each transfection was performed in triplicate. Colonies consisting of more than 10 cells were scored as positive. Values 
represent averages and standard deviations of colony formation normalized to total cell number within 5 randomly selected fields of view. 
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Fig. 4. Suppression of colony formation of a Ras-transformed cell 
line by PAK/RD. Ha-ras-transformed cell line, 29-1, was stably 
transfected with the empty vector (bar 1), RaclNl7 (bar 2), PAK/ 
RD (5 ug per 10 cm dish) (bar 3), and PAK/RD (20 ug/dish, bar 
4). The amount of transfected DNA adjusted to 20 (xg per dish with 
the empty vector. Colonies consisting of more than 10 cells were 
scored as positive. Values represent averages and standard devia-
tions of colony formation normalized to total cell number within 
5 randomly selected fields of view. Bars indicate the averages and 
standard deviations of triplicate. 
4. Discussion 
In this report, we have shown that expression of constitu-
tively activated Rac (RaclV12) in 3Y1 cells leads to transcrip-
tional activation via a TRE. This activation is inhibited by 
RaclN17, but not by RasN17, suggesting that Racl acts 
downstream of Ras in the c-Jun activation pathway. We 
also examined effects of a mutant of p65PAK, PAK/RD, on 
the TRE activation and cell transformation caused by the 
Ras-Rac pathway. PAK/RD markedly antagonized cell trans-
formation as well as TRE activation by RasV12 and 
RaclVI2. PAK/RD lacks the C-terminal catalytic domain, 
but has the N-terminal regulatory domain, which contains 
the CRIB motif, a minimal consensus sequence required for 
the binding of Rac and/or Cdc42. Therefore, PAK/RD is 
thought to inhibit the functions of cellular targets of Rac/ 
Cdc42 by titrating out endogenous Rac and Cdc42. 
onstrated a flattened and cobblestone-like growth pattern like 
that of untransformed control cells (Fig. 3D,E). Coexpression 
of RaclN17 with RasV12 inhibited oncogenic Ras-induced 
colony formation to the level of negative control as previously 
reported (Table 1) [8]. Coexpression of PAK/RD inhibited 
colony formation by RasV12, being comparable to 
RaclN17, as well as colony formation by RaclV12 (Table 1 
and Fig. 3F). Similar results were observed in three independ-
ently performed experiments (Table 1) Coexpression of PAK/ 
RD did not affect the expression level of RasV12 or RaclV12 
(data not shown). 
In order to confirm the inhibitory effect of PAK/RD on 
transformation by RasV12 further, the 29-1 cell line, which 
was previously established by introducing a constitutively ac-
tivated form of Ha-Ras into NIH3T3 cells [33], was stably 
transfected with PAK/RD. As shown in Figs. 4 and 5A, cells 
transfected with control selection vector alone showed signifi-
cantly high colony formation activity. In contrast, introduc-
tion of PAK/RD suppressed colony formation of 29-1 cells in 
a dose-dependent manner, being comparable to the level seen 
in cells transfected with RaclN17 (Fig. 4). The size of colonies 
detected in PAK/RD-transfected cells, if any, was much small-
er than that of vector-transfected cells (Fig. 5B). These results 
suggest that PAK/RD suppressed the Ras-Rac-induced cell 
transformation by inhibiting the functions of Rac/Cdc42 in-
teracting molecules. 
Fig. 5. Morphology of colonies in soft agar. Phase contrast photo-
graphs of cells from the Ha-ras-transformed NIH3T3 cell line 29-1: 
(A) stably expressed empty vector, (B) stably expressed RaclN17, 
and (C) stably expressed PAK/RD. Magnification: X40. 
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Inhibitory effects of the N-terminal regulatory domain of 
hPAK65 [35], one of the isozymes of p65PAK, have been also 
reported [15]. The regulatory domain of hPAK65 (PAKR) 
inhibited JNK1 activation by constitutively activated Cdc42, 
and Dbl, which acts as an exchange factor for Cdc42 and 
RhoA [15]. As PAKR also contains the CRIB motif, the 
mechanism by which PAKR exerts its inhibitory effects seems 
to be similar to that of PAK/RD. More than 25 proteins 
containing the CRIB motif have been recently identified, in-
cluding the growing members of the Ste20- and p65PAK-re-
lated kinases [29]. Thus, the CRIB motif-containing domains 
from these proteins could act as good tools to block specifi-
cally the functions of Rac and Cdc42. 
In order to understand the biochemical basis underlying a 
wide range of the biological effects of Rac and Cdc42, several 
cellular targets of Rac and Cdc42 have been identified [21-
23,36,37]. Recently, using mutants of Rac and Cdc42 which 
harbor amino acid substitutions in the effector loop of the 
these GTPases, the roles of some of these target proteins 
have been analyzed [37]. A Y40C substitution in the effector 
loop of Rac and Cdc42 was not able to interact with p65PAK, 
and could activate neither p65PAK nor the JNK/SAPK path-
way. Despite this, Y40C-substituted Rac and Cdc42 were still 
able to induce actin polymerization and DNA synthesis. 
These results suggest that p65PAK activation by Rac and 
Cdc42 followed by the activation of the JNK/SAPK pathway 
are not required for cell transformation induced by RaclV12 
[37]. Consistent with this, to date there is no report that the 
components of the JNK/SAPK pathway, such as MEKK, 
JNKK/SEK1/MKK3, and JNK/SAPK could cause cell trans-
formation. We also showed that overexpression of wild-type 
p65PAK in NIH 3T3 cells did not increase the colony forming 
activity. However, wild-type p65PAK is not necessarily in its 
active state. In the case of MAPK kinase (MEK), overexpres-
sion of constitutively activated forms of MEK, but not wild-
type MEK, caused transformation in NIH3T3 cells [38,39] 
and differentiation in PC 12 cells [38]. The transforming activ-
ity of a constitutively activated form of p65PAK will be needed 
to address this question. 
Previous reports suggest that cell transformation by Ras 
bifurcates into two pathways, Rac/Rho-dependent pathway 
and Raf-dependent pathway [8-11]. The Raf-dependent path-
way is linked to the ERK pathway, and the involvement of 
ERK in transformation of NIH3T3 has been reported [38,39]. 
On the other hand, the downstream components of the Rac/ 
Rho-dependent pathway are still unknown. One of the possi-
ble candidates integrated into the pathway of Rac/Rho-de-
pendent cell transformation is pl60ROCK . pl60ROCK , originally 
identified as a Ser/Thr kinase that interacts with Rho [23], can 
also bind to Rac in vitro in a GTP-dependent fashion [37]. 
The study using a mutant harboring a F37A substitution in 
the effector loop of Rac showed that this mutant was not able 
to interact with pl60ROCK or induce DNA synthesis, suggest-
ing that the interaction between Rac and pl60ROCK is required 
for cell growth [37]. The Rho family of GTPases also activate 
PI3 kinase [4CM2] and pp70S6K [19], both of which are key 
mediators of mitogenic stimuli. It will be of great interest to 
determine the interactions among these kinases in cell growth 
and transformation. 
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